October Newsletter

Posted:
12
December 2007

Gain Regulatory Approval in the UK in less than 14 Days!Calling all Sponsors!Are you concerned about Regulatory Approval timelines in the UK?Richmond Pharmacology has recently undertaken an analysis of all studies conducted in our units over the past two years and the results speak for themselves. The average approval time for Phase I studies conducted at Richmond Pharmacology since early 2006 is 13.65 days. This is in line with the MHRA's own performance metrics published on their website. If you have any questions regarding gaining regulatory approval for your study, please contact us.Conference & EventsPartnerships In Clinical Trials - 5th - 8th November, AmsterdamBook via Richmond Pharmacology and receive a 25% discount on the delegate fee!Richmond Pharmacology will be exhibiting at the Partnerships in Clinical Trials Conference, the largest gathering of clinical trials outsourcing professionals in Europe. For full details of the Conference Programme please visit the CTC websiteWe very much look forward to meeting you at this conference. If your time at the conference is limited and you wanted to arrange a time convenient for you to meet the Richmond Pharmacology team please contact Charlotte Gowling.To enter this years' most exciting prize draw to win a trip to New York, stop by booth number 15!To register and receive a 25% discount, please visit the website and enter VIP Code CQ3002RICQTc StudiesIs your QTc study putting pressure on your budget?Over the past four years, and many QTc studies later, Richmond Pharmacology has demonstrated an ever improving performance in the quality of ECG's taken at the bedside in our clinics and processed in our ECG Core Laboratory. Our statistician has reviewed all the data produced and we are consistently driving the variability of the ECG reading down to a level unparalleled in the industry. The result of this is that due to the high quality of our ECG readings you have the ability to conduct a thorough QT study (TQT) in a much smaller sample size. Recent experience has shown that Richmond Pharmacology can bring TQT budgets down by as much as 50%.To get access to world-leading Cardiologist, Prof. A.J. Camm and to discuss the study design of your TQT study with the Richmond Pharmacology QTc Specialist Team contact Charlotte Gowling.Join the Buzz surrounding conducting your TQT study at Richmond Pharmacology and meet QT Bee.Our ServicesMeet your outsourcing needs all under one roof!As the UK's largest Early Phase CRO, boasting one of the largest Volunteer Databases of over 75,000 subjects, Richmond Pharmacology is the CRO of choice amongst many of the Top 20 Pharmaceutical Companies. To discuss your Early Phase outsourcing requirements from Protocol to Report, contact Charlotte Gowling.& Finally...Feedback for free Jelly Belly Beans!Richmond Pharmacology are constantly striving to improve our services and as a result we would like to hear your views on us as a company and the services that we provide.If you are interested in taking part in a short piece of market research then please contact Helen Bayliss. We will send you a test tube of Jelly Belly Beans as a token of our gratitude.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more